As part of a post-approval commitment requested by the Ministry of Food and Drug Safety (MFDS), this open-label, single-arm, multicentre, observational Post-Marketing Surveillance (PMS) study aims to characterize the safety profile of Breztri in real-world clinical practice settings, either confirming known safety outcomes or identifying previously unsuspected adverse drug reactions. The study will also evaluate effectiveness of Breztri in real-world clinical practice settings, generating essential clinical evidence from a broader and more diverse Korean patient population representative of daily medical practice.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence proportion of Adverse Events (AEs)/Adverse Drug Reactions (ADRs)
Timeframe: 24 weeks
Incidence proportion of Serious AEs (SAEs)/Serious ADRs (SADRs)
Timeframe: 24 weeks
Incidence proportion of Unexpected AEs/Unexpected ADRs
Timeframe: 24 weeks
Incidence proportion of Unexpected SAEs/Unexpected SADRs
Timeframe: 24 weeks
AstraZeneca Clinical Study Information Center